US 2011/0256154 A1Published application

Anti-erbb3 antibodies

AssigneeAVEO Pharmaceuticals, Inc.

InventorsSylvie Vincent, William M. Winston, JR., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Botega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris

Life of this patent

Estimating the term…

Abstract

Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.

Claims52

Dependent claims

An isolated antibody that binds human ErbB3 comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region selected from the group consisting of:

(a) (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
57 (24C05) and SEQ ID NO:
75 (24C05), a CDRH2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
58 (24C05) and SEQ ID NO:
148 (Sh24C05 Hv3-11 N62S), and a CDRH3 comprising the amino acid sequence of SEQ ID NO:59 (24C05);
and
(ii) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
60 (24C05), a CDRL2 comprising the amino acid sequence of SEQ ID NO:
61 (24C05), and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
62 (24C05);
(b) (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:
5 (04D01), a CDRH2 comprising the amino acid sequence of SEQ ID NO:
6 (04D01), and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
7 (04D01);
and
(ii) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
8 (04D01), a CDRL2 comprising the amino acid sequence of SEQ ID NO:
9 (04D01), and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
10 (04D01);
(c) (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:
15 (09D03), a CDRH2 comprising the amino acid sequence of SEQ ID NO:
16 (09D03), and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
17 (09D03);
and
(ii) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
18 (09D03), a CDRL2 comprising the amino acid sequence of SEQ ID NO:
19 (09D03), and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
(09D03);
(d) (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the s amino acid sequence of SEQ ID NO:
25 (11G01), a CDRH2 comprising the amino acid sequence of SEQ ID NO:
26 (11G01), and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
27 (11G01);
and
(ii) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
28 (11G01), a CDRL2 comprising the amino acid sequence of SEQ ID NO:
9 (11G01), and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
29 (11G01);
(e) (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:
34 (12A07), a CDRH2 comprising the amino acid sequence of SEQ ID NO:
35 (12A07), and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
36 (12A07);
and
(ii) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
8 (12A07), a CDRL2 comprising the amino acid sequence of SEQ ID NO:
9 (12A07), and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
10 (12A07);
(f) (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:
41 (18H02), a CDRH2 comprising the amino acid sequence of SEQ ID NO:
42 (18H02), and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
43 (18H02);
and
(ii) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
44 (18H02), a CDRL2 comprising the amino acid sequence of SEQ ID NO:
45 (18H02), and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
46 (18H02);
and
(g) (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:
51 (22A02), a CDRH2 comprising the amino acid sequence of SEQ ID NO:
52 (22A02), and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
36 (22A02);
and
(ii) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
8 (22A02), a CDRL2 comprising the amino acid sequence of SEQ ID NO:
9 (22A02), and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
10 (22A02).

62 more elements

An isolated antibody that binds human ErbB3 comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region selected from the group consisting of:

(a) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
54 (24C05), and
an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO:
56 (24C05);
(b) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
154 (Sh24C05 Hv3-11 N62S), and
an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO:
168 (Sh24C05 Kv1-17);
(c) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
154 (Sh24C05 Hv3-11 N62S), and
an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO:
166 (Sh24C05 Kv1-16);
(d) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
2 (04D01), and
an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO:
4 (04D01);
(e) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
12 (09D03), and
an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO:
14 (09D03);
(f) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
22 (11G01), and
an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO:
24 (11G01);
(g) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
31 (12A07), and
an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO:
33 (12A07);
(h) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
38 (18H02), and
an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO:
40 (18H02);
and
(i) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
48 (22A02), and
an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO:
50 (22A02).

34 more elements

An isolated antibody that binds human ErbB3 comprising an immunoglobulin heavy chain and an immunoglobulin light chain selected from the group consisting of:

(a) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO:
133 (24C05), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:
135 (24C05);
(b) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO:
190 (Sh24C05 Hv3-11 N62S IgG1), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:
206 (Sh24C05 Kv1-17 kappa);
(c) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO:
190 (Sh24C05 Hv3-11 N62S IgG1), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:
204 (Sh24C05 Kv1-16 kappa);
(d) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO:
109 (04D01), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:
111 (04D01);
(e) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO:
113 (09D03), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:
115 (09D03);
(f) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO:
117 (11G01), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:
119 (11G01);
(g) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO:
121 (12A07), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:
123 (12A07);
(h) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO:
125 (18H02), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:
127 (18H024);
and
(i) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO:
129 (22A02), and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:
131 (22A02).

25 more elements

Dependencies are inferred from the claim text.

Facts

Application: 13/082,852Filed 8 Apr 2011
Priority: 9 Apr 2010
Published: 20 Oct 2011
Term ends: Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 16/32
Against material from animals or humans: against translation products of oncogenes
A61P 35/00
Antineoplastic agents
C07K 16/30
Against receptors, cell surface antigens or cell surface determinants: from tumour cells
A61K 39/39558
Against materials from animals: against tumor tissues, cells, antigens

Family

Application61/322,712Us provisional application · filed 9 Apr 2010
US 8,481,687 B2Related patent
US 2011/0256154 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

An isolated antibody that binds human ErbB3 comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region selected from the group consisting of:

(a) (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
57 (24C05) and SEQ ID NO:
75 (24C05), a CDRH2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
58 (24C05) and SEQ ID NO:
148 (Sh24C05 Hv3-11 N62S), and a CDRH3 comprising the amino acid sequence of SEQ ID NO:59 (24C05);
and
(ii) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
60 (24C05), a CDRL2 comprising the amino acid sequence of SEQ ID NO:
61 (24C05), and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
62 (24C05);
(b) (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:
5 (04D01), a CDRH2 comprising the amino acid sequence of SEQ ID NO:
6 (04D01), and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
7 (04D01);
and
(ii) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
8 (04D01), a CDRL2 comprising the amino acid sequence of SEQ ID NO:
9 (04D01), and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
10 (04D01);
(c) (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:
15 (09D03), a CDRH2 comprising the amino acid sequence of SEQ ID NO:
16 (09D03), and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
17 (09D03);
and
(ii) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
18 (09D03), a CDRL2 comprising the amino acid sequence of SEQ ID NO:
19 (09D03), and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
(09D03);
(d) (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the s amino acid sequence of SEQ ID NO:
25 (11G01), a CDRH2 comprising the amino acid sequence of SEQ ID NO:
26 (11G01), and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
27 (11G01);
and
(ii) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
28 (11G01), a CDRL2 comprising the amino acid sequence of SEQ ID NO:
9 (11G01), and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
29 (11G01);
(e) (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:
34 (12A07), a CDRH2 comprising the amino acid sequence of SEQ ID NO:
35 (12A07), and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
36 (12A07);
and
(ii) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
8 (12A07), a CDRL2 comprising the amino acid sequence of SEQ ID NO:
9 (12A07), and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
10 (12A07);
(f) (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:
41 (18H02), a CDRH2 comprising the amino acid sequence of SEQ ID NO:
42 (18H02), and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
43 (18H02);
and
(ii) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
44 (18H02), a CDRL2 comprising the amino acid sequence of SEQ ID NO:
45 (18H02), and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
46 (18H02);
and
(g) (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:
51 (22A02), a CDRH2 comprising the amino acid sequence of SEQ ID NO:
52 (22A02), and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
36 (22A02);
and
(ii) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
8 (22A02), a CDRL2 comprising the amino acid sequence of SEQ ID NO:
9 (22A02), and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
10 (22A02).

62 more elements

Facts

Application

13/082,852Filed 8 Apr 2011

Priority

9 Apr 2010

Published

20 Oct 2011

Term ends

Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 16/32
Against material from animals or humans: against translation products of oncogenes
A61P 35/00
Antineoplastic agents
C07K 16/30
Against receptors, cell surface antigens or cell surface determinants: from tumour cells
A61K 39/39558
Against materials from animals: against tumor tissues, cells, antigens